Immobilized HLA-A*03:01&B2M&KRAS G12V (VVVGAVGVGK) Tetramer, His & Avi, Human, His Tag at 5 μg/ml (100 μl/well) on the plate. Dose response curve for Anti-HLA-A*03:01&B2M&KRAS G12VAntibody, hFc Tag with the EC50 of 0.19 μg/ml determined by ELISA.

The purity of HLA-A*03:01&B2M&KRAS G12V (VVVGAVGVGK) Tetramer, His & Avi, Human is greater than 95% as determined by SEC-HPLC.

HLA-A*03:01&B2M&KRAS G12V (VVVGAVGVGK) Tetramer, His & Avi, Human on Bis-Tris PAGE under Non reducing (N) condition. The purity is greater than 95%.

Anti-HLA-A*03:01&B2M&KRAS G12V (VVVGAVGVGK) Antibody captured on CM5 Chip via Protein A can bind HLA-A*03:01&B2M&KRAS G12V (VVVGAVGVGK) TetraAmer, His & Avi, Human, His Tag with an affinity constant of 42.3 nM as determined in SPR assay (Biacore T200).

HLA-A*03:01&B2M&KRAS G12V (VVVGAVGVGK) Tetramer, His & Avi, Human

Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.

Cat. No.	Z06606
Size	100 μg : Quote 500 μg : Quote Buy in bulk
Quantity
Price	¥208,928.00


Ask us a question

Product Introduction

Species

Human

Protein Construction

HLA-A03:01&B2M&KRAS G12V (VVVGAVGVGK) Tetramer[Gly25-Thr305(HLA-A03:01), Ile21-Met119(B2M) and VVVGAVGVGK peptide] Accession # NP_002107.3(HLA-A*03:01)&P61769(B2M)&VVVGAVGVGK	His	Avi
N-term		C-term

Purity

> 95% as determined by BisTris PAGE
> 95% as determined by HPLC

Endotoxin Level

Less than 1EU per μg by the LAL method.

Biological Activity

Measured by its binding ability in a functional ELISA. Immobilized HLA-A*03:01&B2M&KRAS G12V (VVVGAVGVGK) Tetramer, His & Avi, Human at 5μg/ml (100μl/Well) on the plate can bind Anti-HLA-A*03:01&B2M&KRAS G12V (VVVGAVGVGK) Antibody, hFc Tag. Test result was comparable to standard batch.

Expression System

HEK293

Theoretical Molecular Weight

258 kDa

Apparent Molecular Weight

Due to glycosylation, the protein migrates to 260-265 kDa under Non reducing (N) condition based on Bis-Tris PAGE result.

Formulation

Lyophilized from 0.22μm filtered solution in PBS (pH 7.4).

Reconstitution

Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.

Storage & Stability

Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles.

Examples

The purity of HLA-A*03:01&B2M&KRAS G12V (VVVGAVGVGK) Tetramer, His & Avi, Human is greater than 95% as determined by SEC-HPLC.

HLA-A*03:01&B2M&KRAS G12V (VVVGAVGVGK) Tetramer, His & Avi, Human on Bis-Tris PAGE under Non reducing (N) condition. The purity is greater than 95%.

Background

Target Background	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
Synonyms	MHC; KRAS; K-Ras 2; KRAS2; C-K-RAS; CFC2; K-RAS2A; K-RAS2B; K-RAS4A; K-RAS4B; KRAS1; KRAS2; NS; NS3; RASK2; GTPase Kras; KI-RAS; RALD

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.

HLA-A*03:01&B2M&KRAS G12V (VVVGAVGVGK) Tetramer, His & Avi, Human

サポート

会社情報

サポート

会社情報